World Congress on Biologics and Biosimilars

Biosimilars Conferences | Biologics Conferences | Pharmaceutical Conference 2026 - Barcelona
Join the World Congress on Biologics and Biosimilars from May 18-19, 2026, in Barcelona, Spain, to explore advances in biologic therapies and biosimilar development with global experts & researchers.

Theme: Next-Gen Biologics and Biosimilars: Transforming Global Healthcare

Attending thisWorld Congress on Biologics and BiosimilarsduringMay 18-19, 2026atBarcelona, Spain, presents a valuable opportunity for professionals, researchers, academics, and industry leaders involved in the development, regulation, and commercialization of biosimilar and biologic medicines.Biosimilars Conferenceserves as a dynamic platform for knowledge exchange, professional networking, and staying updated with the rapidly evolving landscape of biosimilar therapies. As global demand for cost-effective biologic alternatives continues to rise, understanding the complexities and advancements in biosimilars is essential for anyone involved in pharmaceutical sciences, regulatory affairs, clinical research, or healthcare policy. The event typically brings together a diverse community of stakeholders, including scientists,regulatory authorities, healthcare providers, biotech companies, and academic institutions, fostering an environment where ideas are exchanged, collaborations are formed, and innovations are showcased.
In addition to panel discussions, speaker and poster presentations offer a platform for both established professionals and emerging researchers to present their latest findings, methodologies, and case studies. This exposure can lead to constructive feedback, potential research collaborations, and increased visibility within the scientific community. Furthermore, thisBiosimilars Conferenceoften feature round table meetings, which are particularly valuable for fostering deeper conversations between industry leaders and academic experts. These intimate settings promote targeted discussions on specific issues such as biosimilar uptake, pricing strategies, and patient education.